Hypertension and chronic kidney disease progression: Why the suboptimal outcomes?

American Journal of Medicine

Volumn 125, Issue 11, 2012, Pages 1057-1062

  Bidani, Anil K ^a   Griffin, Karen A ^a   Epstein, Murray ^b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Ambulatory blood pressure monitoring; Antihypertensive agents; Blood pressure lability; Masked hypertension; Renal autoregulation

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CIRCADIAN RHYTHM; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE PREDISPOSITION; DIURESIS; DRUG DELIVERY SYSTEM; GLOMERULUS CAPILLARY; HUMAN; HYPERTENSION; KIDNEY FUNCTION; NEPHROSCLEROSIS; PATHOPHYSIOLOGY; PATIENT EDUCATION; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; DISEASE PROGRESSION; HUMANS; HYPERTENSION; RENAL INSUFFICIENCY, CHRONIC;

EID: 84867852348     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2012.04.008     Document Type: Review

References (50)

1. W. Chobanian, G.L. Bakris, H.R. Black Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure Hypertension 42 2003 1206 1252
2. Kidney Disease Outcomes Quality Initiative (KDOQI) KDOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease Am J Kidney Dis 43 Suppl 1 2004 S1 S290
3. L.J. Appel, J.T. Wright Jr, T. Green African American Study of Kidney Disease Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans Arch Intern Med 168 2008 832 839
4. L.J. Appel, J.T. Wright Jr, T. Green AASK Collaborative Research Group Intensive blood-pressure control in hypertensive chronic kidney disease N Engl J Med 363 2010 918 929
5. J.B. Kopp, M.W. Smith, G.W. Nelson MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis Nat Genet 40 2008 1175 1184
6. W.H. Kao, M.J. Klag, L.A. Meoni Family Investigation of Nephropathy and Diabetes Research Group MYH9 is associated with nondiabetic end-stage renal disease in African-Americans Nat Genet 40 2008 1185 1192
7. G. Genovese, D.J. Friedman, M.D. Ross Association of trypanolytic apoL1 variants with kidney disease in African-Americans Science 329 2010 841 845
8. T.H. Jafar, P.C. Stark, C.H. Schmid AIPRD Study Group Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition A patient-level meta-analysis Ann Intern Med 139 2003 244 252
9. E.J. Lewis, L.G. Hunsicker, R.P. Bain, R.D. Rohde for the Collaborative Study Group The effects of angiotensin-converting-enzyme inhibition on diabetic nephropathy N Engl J Med 329 1993 1456 1462
10. E.J. Lewis, L.G. Hunsicker, W.R. Clarke Collaborative Study Group Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
11. B.M. Brenner, M.E. Cooper, D. de Zeeuw Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
12. H.W. Schnaper, S.C. Hubchak, C.E. Runyan A conceptual framework for the molecular pathogenesis of progressive kidney disease Pediatr Nephrol 25 2010 2223 2230
13. P. Boor, T. Ostendorf, J. Floege Renal fibrosis: novel insights into mechanisms and therapeutic targets Nat Rev Nephrol 6 2010 643 656
14. J.F. Mann, R.E. Schmieder, M. McQueen ONTARGET Investigators Renal outcomes with temisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blinded, controlled trial Lancet 372 2008 547 553
15. M. Epstein Re-examining RAS-blocking treatment regimens for abrogating progression of chronic kidney disease Nat Clin Pract Nephrol 5 2009 12 13
16. S. Wood ALTITUDE halted: adverse events when aliskiren added to ACE, ARB therapy http://www.theheart.org/article/1331173.do Accessed March 28, 2012
17. ACCORD Study Group Effects of intensive blood-pressure control in type 2 diabetes mellitus N Engl J Med 362 2010 1575 1585
18. A. Upadhyay, A. Earley, S.M. Haynes, K. Uhlig Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier Ann Intern Med 154 2011 541 548
19. S. Klahr, A.S. Levey, G.J. Beck Modification of Diet in Renal Disease Study Group The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease N Engl J Med 330 1994 877 884
20. P. Ruggenenti, A. Perna, G. Loriga REIN-2 Study Group Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomized controlled trial Lancet 365 2005 939 946
21. A.K. Bidani, K.A. Griffin Pathophysiology of hypertensive renal damage: implications for therapy Hypertension 44 2004 595 601
22. G.S. Hill Hypertensive nephrosclerosis Curr Opin Nephrol Hypertens 17 2008 266 270
23. R. Loutzenhiser, K.A. Griffin, G. Williamson, A.K. Bidani Renal autoregulation: new perspectives regarding the protective and regulatory roles of the underlying mechanisms Am J Physiol 290 2006 R1153 R1167
24. K.A. Griffin, A.K. Bidani Angiotensin II type 2 receptor in chronic kidney disease: the good side of angiotensin II? Kidney Int 75 2009 1006 1008
25. T.W. Kurtz False claims of blood pressure-independent protection by blockade of the renin angiotensin aldosterone system? Hypertension 41 2003 193 196
26. A.K. Bidani, K.A. Griffin Blood pressure targets in chronic kidney disease Nat Rev Nephrol 7 2011 128 130
27. W.B.A. Eijkelkamp, Z. Zhang, G. Remuzzi Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the reduction of endpoints in NIDDM with the angiotensin II antagonist Losartan (RENAAL) trial J Am Soc Nephrol 18 2007 1540 1546
28. A.K. Bidani, K.A. Griffin, G. Williamson, X. Wang, R. Loutzenhiser Protective importance of the myogenic response in the renal circulation Hypertension 54 2009 393 398
29. K.A. Griffin, M.M. Picken, A.K. Bidani Blood pressure lability and glomerulosclerosis after normotensive 5/6 renal mass reduction in the rat Kidney Int 65 2004 209 218
30. T.W. Kurtz, K.A. Griffin, A.K. Bidani, R.L. Davisson, J.E. Hall AHA Scientific Statement: recommendations for blood pressure measurements in humans and animals Part 2: Blood pressure measurements in experimental animals Hypertension 45 2005 299 310
31. V. Pogue, M. Rahman, M. Lipkowitz African American Study of Kidney Disease Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease Hypertension 53 2009 20 27
32. E.M. Davis, L.J. Appel, X. Wang African American Study of Kidney Disease and Hypertension Research Collaborative Group Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial Hypertension 57 2011 1061 1068
33. M. Bursztyn, I.Z. Ben-Dov Intensive blood-pressure control in hypertensive chronic kidney disease N Engl J Med 363 2010 2564
34. T.G. Pickering, J.E. Hall, L.J. Appel Recommendations for blood pressure measurements in humans and experimental animals Part 1: blood pressure measurements in humans. A statement for professionals from the subcommittee of professional and public education of the American Heart Association Council on High Blood Pressure Research Hypertension 45 2005 142 161
35. P.M. Rothwell, S.C. Howard, E. Dolan Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension Lancet 375 2010 895 905
36. P.M. Rothwell Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension Lancet 375 2010 938 948
37. M.B. Davidson, J.K. Hix, D.G. Vidt, D.J. Brotman Association of impaired diurnal blood pressure variation with a subsequent decline in glomerular filtration rate Arch Intern Med 166 2006 846 852
38. R. Agarwal Ambulatory blood pressure and cardiovascular events in chronic kidney disease Semin Nephrol 27 2007 538 543
39. R.C. Hermida, D.E. Ayala, A. Mojon, J.R. Fernandez Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes Diabetes Care 34 2011 1270 1276
40. R.C. Hermida, D.E. Ayala, A. Mojon, J.R. Fernandez Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD J Am Soc Nephrol 22 2011 2313 2321
41. Hypertension: clinical management of primary hypertension in adults (update). Clinical Guidelines 127, 2011 National Institute for Health and Clinical Excellence http://guidance.nice.org.uk/CG127 Accessed April 16, 2012
42. M.J. Bloch, J.N. Basile UK guidelines call for routine 24-hour ambulatory blood pressure monitoring in all patients to make the diagnosis of hypertension-not ready for prime time in the United States J Clin Hypertens 13 2011 871 872
43. G.L. Bakris, M.R. Weir Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches J Clin Hypertens 6 2008 202 209
44. G. Parati, H. Schumacher, G. Bilo, G. Mancia Evaluating 24-h antihypertensive efficacy by the smoothness index: a meta-analysis of an ambulatory blood pressure monitoring database J Hypertens 28 2010 2177 2183
45. H.L. Elliott, P.A. Meredith Trough:peak ratio: clinically useful or practically irrelevant? J Hypertens 13 1995 279 283
46. F. Agnès Matzinger, A. Zannad, J. Larché Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists Am J Hypertens 9 1996 633 643
47. H.J. Kloke, A.J. Branten, F.T. Huysmans, J.F. Wetzels Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers? Kidney Int 53 1998 1559 1573
48. G.L. Bakris, M.R. Weir, M. Secic, B. Campell, A. Weis-NcNulty Differential effects of calcium antagonist subclasses on markers of nephropathy progression Kidney Int 65 2004 1991 2002
49. J.T. Wright Jr, G. Bakris, T. Greene African American Study of Kidney Disease and Hypertension Study Group Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease Results from the AASK Trial JAMA 288 2002 2421 2467
50. K.A. Griffin, M.M. Picken, A.K. Bidani Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys J Clin Invest 96 1995 793 800